Literature DB >> 2937738

Chemotherapeutic effects of ofloxacin (HOE 280) and other quinolone-carboxylic derivates in the treatment of experimental lung infections due to Klebsiella pneumoniae DT-S in mice.

N Klesel, M Limbert, G Seibert, I Winkler, E Schrinner.   

Abstract

The chemotherapeutic activity of ofloxacin (HOE 280), a new pyridone-carboxylic acid derivative, was compared with that of other drugs in the same group, including norfloxacin, ciprofloxacin, enoxacin and in some cases pipemidic acid and nalidixic acid. The test model used was experimental pneumonia caused by Klebsiella pneumoniae DT-S in mice. In the treatment of pneumonic mice, ofloxacin was 4 to 18 times more effective than norfloxacin and enoxacin and in most cases slightly more effective than ciprofloxacin. Pipemidic acid and nalidixic acid showed only low activity or proved to be inactive. In studies on the bactericidal activity of the compounds in vivo, ofloxacin produced a more pronounced effect than ciprofloxacin. With norfloxacin and enoxacin, a bactericidal effect in the infected tissue of the animals was only observed during the first hours after treatment.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2937738     DOI: 10.1007/bf01645196

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  9 in total

1.  Pharmacokinetics and tissue penetration of ciprofloxacin.

Authors:  B Crump; R Wise; J Dent
Journal:  Antimicrob Agents Chemother       Date:  1983-11       Impact factor: 5.191

2.  Potential usefulness of norfloxacin in the treatment of urinary tract infections.

Authors:  S R Norrby
Journal:  Eur J Clin Microbiol       Date:  1983-06       Impact factor: 3.267

3.  Therapeutic effects of cefotiam and cefazolin on experimental pneumonia caused by Klebsiella pneumoniae DT-S in mice.

Authors:  T Nishi; K Tsuchiya
Journal:  Antimicrob Agents Chemother       Date:  1980-10       Impact factor: 5.191

4.  Experimental respiratory tract infection with Klebsiella pneumoniae DT-S in mice: chemotherapy with kanamycin.

Authors:  T Nishi; K Tsuchiya
Journal:  Antimicrob Agents Chemother       Date:  1980-03       Impact factor: 5.191

5.  Comparison of the antibacterial in vitro and in vivo activity of ofloxacin (HOE 280 DL 8280) and nalidixic acid analogues.

Authors:  G Seibert; M Limbert; N Klesel
Journal:  Eur J Clin Microbiol       Date:  1983-12       Impact factor: 3.267

6.  Cefodizime, an aminothiazolyl cephalosporin. III. Therapeutic activity against experimentally induced pneumonia in mice.

Authors:  N Klesel; M Limbert; G Seibert; I Winkler; E Schrinner
Journal:  J Antibiot (Tokyo)       Date:  1984-12       Impact factor: 2.649

7.  Cefodizime, an aminothiazolylcephalosporin. II. Comparative studies on the pharmacokinetic behavior in laboratory animals.

Authors:  N Klesel; M Limbert; K Seeger; G Seibert; I Winkler; E Schrinner
Journal:  J Antibiot (Tokyo)       Date:  1984-08       Impact factor: 2.649

8.  In vitro and in vivo activity of DL-8280, a new oxazine derivative.

Authors:  K Sato; Y Matsuura; M Inoue; T Une; Y Osada; H Ogawa; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1982-10       Impact factor: 5.191

9.  Pharmacokinetics and tissue penetration of enoxacin.

Authors:  R Wise; R Lockley; J Dent; M Webberly
Journal:  Antimicrob Agents Chemother       Date:  1984-07       Impact factor: 5.191

  9 in total
  2 in total

1.  Ofloxacin in lower respiratory tract infections.

Authors:  P Hänninen
Journal:  Drugs       Date:  1987       Impact factor: 9.546

Review 2.  Ofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  J P Monk; D M Campoli-Richards
Journal:  Drugs       Date:  1987-04       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.